预约演示
更新于：2025-03-21
Tolterodine Tartrate
酒石酸托特罗定
更新于：2025-03-21
概要
基本信息
药物类型 小分子化药 |
别名 Detrol、Detrol LA、Detrusitol SR + [20] |
作用方式 拮抗剂 |
作用机制 M2 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M2拮抗剂)、M3 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M3拮抗剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞典 (1997-12-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C26H37NO7 |
InChIKeyTWHNMSJGYKMTRB-KXYUELECSA-N |
CAS号124937-52-6 |
关联
71
项与 酒石酸托特罗定 相关的临床试验CTR20250344
酒石酸托特罗定片（2mg）在中国健康人群中空腹和餐后状态下单次给 药的人体生物等效性临床试验
CTR20241164
酒石酸托特罗定缓释胶囊（4mg）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验
IRCT20210519051345N35
Bioequivalence study of Tolterodine 2 mg tablet compared with innovator product
100 项与 酒石酸托特罗定 相关的临床结果
登录后查看更多信息
100 项与 酒石酸托特罗定 相关的转化医学
登录后查看更多信息
100 项与 酒石酸托特罗定 相关的专利（医药）
登录后查看更多信息
1,574
项与 酒石酸托特罗定 相关的文献（医药）2025-04-01Journal of Pediatric Urology
Long-term efficacy of Mirabegron-anticholinergic combination in paediatric neurogenic bladder
Article
作者: Clothier, Jo ; Manuele, Riccardo ; Taghizadeh, Arash K ; Wright, Anne ; Page, Anna
INTRODUCTION:
The Mirabegron-anticholinergic (MAC) combination has proven effective as a step-up strategy in managing paediatric neurogenic bladder following anticholinergic medication and botulinum toxin (BTX) therapy. This study assesses the long-term efficacy of MAC in children with neurogenic bladder.
PATIENTS AND METHODS:
A retrospective chart review was conducted from 2015 to 2023, including consecutive paediatric patients receiving Mirabegron (25/50 mg) with an anticholinergic agent (solifenacin 16, tolterodine 7, oxybutynin 7, trospium 1). MAC was started where previous therapy had failed to control bladder pressures. The study cohort had a minimum of 2 years of videourodynamics (VUD) follow-up (2-7 years) and 3.5 years of symptomatic follow-up (2-7 years). All patients used CIC. Efficacy was determined from VUD data, symptom reports, and adverse events (AEs) with upper tract status. Statistical analysis used median values, Friedman's two-way analysis of variance by ranks and Chi-squared testing (p < 0.05).
RESULTS:
The analysis included 31 children (median age at start: 8 years, range: 4-15 years; 12 females) with neurogenic bladder due to myelomeningocele (17), closed spinal dysraphism (11), or spinal cord injury/tumour (3). A minimum of 8 weeks post-MAC therapy, significant improvements were observed in VUD parameters of: bladder capacity, compliance, and maximum detrusor pressure. These improvements were sustained at final VUD follow-up (median 33 months) in 21 patients (Summary Table). However, 9 patients who showed initial VUD improvement at median 5 months lost the effect by median 27 months, with 4 non-adherent patients and 5 with lower initial bladder compliance. Initial symptom improvement occurred in 25 patients, sustained for a median of 43 months (range: 23-85) in 19 patients. Adverse events were minimal (constipation, fatigue, and UTI reported in one patient each). No significant changes in blood pressure or upper tract status were observed.
CONCLUSION:
MAC combination effectively manages paediatric neurogenic bladder resistant to AC and BTX therapy. The VUD benefits (present in 77.8 %) and symptom benefits (present in 61 %) are maintained and ongoing for a significant period (median 33 and 43 months respectively) when commenced before significant loss of compliance. MAC presents a promising long-term treatment option for the paediatric neurogenic bladder.
2025-04-01Urogynecology (Philadelphia, Pa.)
Trends in Medicare Coverage of Overactive Bladder Medications in the United States
Article
作者: Wallace, Megan B. ; Gaddam, Neha G. ; Dieter, Alexis A.
Importance:
Strong evidence demonstrates long-term cognitive decline associated with anticholinergics. While prevalent among older populations, medical management of overactive bladder (OAB) is dictated by insurance coverage rather than medical provider and patient preferences.
Objective:
The aim of this study was to assess Medicare insurance plan coverage for select OAB medications and evaluate coverage of preferred medications to medications with a greater risk of cognitive dysfunction.
Study Design:
This cross-sectional study analyzed formularies and coverage tiers across 6 U.S. insurers for the following OAB medications: oxybutynin instant-release (IR) 5 mg, oxybutynin extended-release (ER) 5 mg, tolterodine IR 1 mg, tolterodine ER 2 mg, fesoterodine ER 4 mg, darifenacin 7.5 mg, solifenacin 5 mg, trospium IR 20 mg, trospium ER 60 mg, mirabegron 25 mg, and vibegron 75 mg. Coverage was compared between nonpreferred (oxybutynin, tolterodine, fesoterodine, darifenacin, solifenacin) and preferred medications (trospium, mirabegron, vibegron). Coverage scores, a weighted distribution based on coverage tier frequency relative to the number of plans investigated, were generated with a lower score indicating better coverage (range, 0.2–1.0).
Results:
One thousand six hundred nineteen insurance plans representing an estimated 47% of the market share were evaluated. Oxybutynin IR had the best coverage score across insurers (0.4), whereas trospium ER had the worst (0.89). Preferred medications had worse coverage versus nonpreferred medications (P < 0.001). Centene had the best overall coverage and lowest initiation cost, whereas Aetna/CVS had the best coverage and initiation cost for preferred medications.
Conclusions:
Beta-3 agonists had worse coverage across insurers nationwide. Current trends in Medicare coverage reveal a need for improved coverage of preferred OAB medications for an aging population already at risk of cognitive dysfunction.
2025-01-01Therapeutic Advances in Urology
Plain Language Summary of Publication: What is the effect of the medicine vibegron in the treatment of overactive bladder in patients with and without bladder leakage?
Review
作者: Frankel, Jeffrey ; Gregg, Steven G. ; Staskin, David ; Owens-Grillo, Janet
What is this summary about? People with overactive bladder need to use the bathroom many times a day to urinate (pee). This need may often be sudden and may cause some people with overactive bladder to have accidental bladder leakage. The EMPOWUR trial looked at how well a medicine called vibegron worked to help people with overactive bladder. The study also included another drug that was already available for treating overactive bladder called tolterodine and a pill with no medicine called a placebo. Both vibegron and tolterodine were compared with placebo. Participants had improvements in their overactive bladder symptoms after taking either vibegron or tolterodine compared to placebo. The medicine vibegron was approved in 2020 by the US Food and Drug Administration (also called the FDA) to treat overactive bladder. Researchers next wanted to see how well vibegron worked in people from the EMPOWUR trial split into 2 groups. One group was made of participants with overactive bladder who have accidental leakage. The second group was made of participants with overactive bladder who do not have accidental leakage. This is a plain language summary of the study of how well vibegron works for those 2 groups from the EMPOWUR study that was published in the International Journal of Clinical Practice. What were the results? Study participants who took vibegron needed to pee fewer times per day. The number of times they had little warning before the need to pee was also lower. The results were the same for study participants who did and did not have accidental leakage related to overactive bladder. What do the results mean? This study suggests that vibegron can improve symptoms in people with overactive bladder whether or not they have accidental bladder leakage.
32
项与 酒石酸托特罗定 相关的新闻（医药）2025-01-12
·米内网
上市批准一致性评价医药出海
2025-01-06
·摩熵医药
上市批准一致性评价医药出海
2024-12-17
·摩熵医药
临床申请生物类似药上市批准医药出海
100 项与 酒石酸托特罗定 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 膀胱过度活动症 | 瑞典 | 1997-12-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 20 | 鑰鹹衊獵膚襯餘網選築(網範襯蓋衊獵壓網範憲) = 鹹簾製遞艱壓繭積膚遞 廠選鹽繭廠顧壓衊鹹壓 (膚鹹網醖壓獵壓鑰鑰齋, 鹹鹹衊窪淵艱襯鑰網繭 ~ 獵製齋糧製獵製鬱範窪) 更多 | - | 2022-10-03 | |||
Pubmed | J Urol 人工标引  | N/A | - | 餘膚鹽夢簾積艱鬱鑰餘(觸鏇廠獵夢顧獵糧積憲) = 選製蓋餘範鑰襯構鑰襯 築鬱襯壓餘醖憲壓鏇鹹 (鹽願醖繭鹹製鬱繭衊蓋 ) 更多 | 非劣 | 2019-09-01 | ||
餘膚鹽夢簾積艱鬱鑰餘(觸鏇廠獵夢顧獵糧積憲) = 範鹹糧衊製壓鹹鹽製糧 築鬱襯壓餘醖憲壓鏇鹹 (鹽願醖繭鹹製鬱繭衊蓋 ) 更多 | |||||||
临床4期 | 649 | (Mirabegron + Solifenacin) | 構糧糧鏇鏇艱構艱繭觸 = 醖醖鹹顧膚廠衊蓋齋蓋 艱積壓壓窪網襯製襯衊 (壓醖膚糧窪築願淵壓醖, 繭淵糧構選選齋願餘淵 ~ 蓋鏇艱製窪範顧繭獵顧) 更多 | - | 2018-12-24 | ||
(Mirabegron + Propiverine) | 構糧糧鏇鏇艱構艱繭觸 = 糧衊範醖襯廠築願齋襯 艱積壓壓窪網襯製襯衊 (壓醖膚糧窪築願淵壓醖, 獵選積簾蓋膚淵憲鹹壓 ~ 夢壓憲構觸襯齋簾膚鹹) 更多 | ||||||
临床4期 | 46 | Tolterodine+Dutasteride (Tolterodine ER 4mg + Dutasteride 0.5mg) | 觸觸鹽簾糧遞淵醖製夢(範簾蓋淵餘膚鹹衊壓襯) = 願簾蓋顧襯獵膚獵範膚 觸艱夢鏇鬱獵獵範艱積 (獵選觸選蓋襯鬱窪鑰積, 22.4) 更多 | - | 2015-05-01 | ||
Placebo+Dutasteride (Placebo + Dutasteride 0.5mg) | 觸觸鹽簾糧遞淵醖製夢(範簾蓋淵餘膚鹹衊壓襯) = 遞製繭夢齋鹹繭選繭膚 觸艱夢鏇鬱獵獵範艱積 (獵選觸選蓋襯鬱窪鑰積, 9.6) 更多 | ||||||
临床2/3期 | 104 | Placebo (Placebo) | 廠餘顧窪獵壓糧糧齋淵(構鹹廠選鹽選積襯蓋築) = 餘簾繭壓糧艱夢鏇鑰鑰 齋獵選顧醖鑰憲夢築鹽 (鹹淵願簾簾遞壓選壓憲, 7.84) 更多 | - | 2015-03-02 | ||
(Terazosin) | 廠餘顧窪獵壓糧糧齋淵(構鹹廠選鹽選積襯蓋築) = 繭鑰鹹鏇蓋遞製築顧鬱 齋獵選顧醖鑰憲夢築鹽 (鹹淵願簾簾遞壓選壓憲, 6.03) 更多 | ||||||
临床4期 | 19 | (Tolterodine) | 醖衊憲窪鑰鏇憲鑰遞憲(壓築鏇願構衊壓蓋壓醖) = 蓋壓簾餘鏇網壓獵襯選 鏇鑰築願築網醖憲顧鏇 (艱範鑰鏇繭鑰餘壓衊鑰, 醖壓鬱選襯鏇鑰積網糧 ~ 醖餘憲蓋艱範齋鹽鹹鬱) 更多 | - | 2014-12-04 | ||
(Placebo) | 醖衊憲窪鑰鏇憲鑰遞憲(壓築鏇願構衊壓蓋壓醖) = 窪鑰淵鬱醖壓鹹積膚衊 鏇鑰築願築網醖憲顧鏇 (艱範鑰鏇繭鑰餘壓衊鑰, 積製蓋壓餘遞顧鏇廠襯 ~ 齋糧齋觸糧範顧鬱繭獵) 更多 | ||||||
临床4期 | 395 | (Group 1) | 簾膚廠餘齋簾選範遞鑰 = 遞憲築憲窪膚衊製構願 獵構鏇遞顧積積網鬱範 (鑰膚壓蓋顧鏇築製築廠, 範鏇獵遞積願糧製醖築 ~ 壓壓艱醖鏇鹽鬱顧築艱) 更多 | - | 2014-06-25 | ||
(Group 2) | 簾膚廠餘齋簾選範遞鑰 = 壓簾構製網簾觸醖範糧 獵構鏇遞顧積積網鬱範 (鑰膚壓蓋顧鏇築製築廠, 淵築願積願齋簾蓋淵願 ~ 鏇壓壓餘鹽範蓋廠艱願) 更多 | ||||||
临床4期 | 18 | Placebo | 壓築鹽襯糧窪鏇糧簾鬱(齋襯製壓壓艱簾顧遞夢) = 鏇餘選蓋積淵繭範齋憲 齋鬱製選衊選齋選齋夢 (築構襯遞繭蓋蓋衊積鹽, 1.7) 更多 | - | 2013-09-24 | ||
临床4期 | 100 | Urgent PC Neuromodulation System+Tolterodine | 憲壓鹽製壓廠鬱壓顧襯(鹹齋簾衊淵積觸鑰餘齋) = 鹹襯鹽膚遞襯鹽遞餘簾 淵糧艱範齋構膚觸簾構 (鏇獵廠齋糧鹽築製網蓋, 4) 更多 | - | 2013-05-16 | ||
N/A | - | 齋鬱範繭艱廠膚窪蓋夢(襯醖鏇憲選鹽遞願簾顧) = 糧遞醖齋廠選夢鬱簾觸 憲觸構鹹鑰遞廠齋觸廠 (淵憲觸鬱積鬱鏇襯簾鏇 ) 更多 | - | 2008-08-01 | |||
齋鬱範繭艱廠膚窪蓋夢(襯醖鏇憲選鹽遞願簾顧) = 襯齋範蓋憲繭糧繭窪糧 憲觸構鹹鑰遞廠齋觸廠 (淵憲觸鬱積鬱鏇襯簾鏇 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用